FLT3 and acute myeloid leukemia: Among drugs in the development pipeline for AML, selective FLT3 inhibitors Crenolanib and ASP2215 have exhibited impressive single-agent activity (ORR 52%, CRC 41%) in a phase I/II study of relapsed/refractory AML79.